A luminescent compound has a structure represented by a general formula (1),

##STR00001##

wherein R represents a luminescent dye skeleton, X represents an ionic substituent, and L represents a single bond, an oxygen atom, a sulfur atom, a selenium atom, or an NH group.

A luminescent compound has a structure represented by a general formula (1),

##STR00001##

wherein R represents a luminescent dye skeleton, X represents an ionic substituent, and L represents a single bond, an oxygen atom, a sulfur atom, a selenium atom, or an NH group.

An organic electroluminescent element including a substrate, a pair of electrodes including an anode and a cathode, disposed on the substrate, and at least one organic layer including a light emitting layer, disposed between the electrodes, in which at least one kind of compound represented by the following general formula is contained in any layer of the at least one organic layer, is an organic electroluminescent element, in which the generation of dark spots during driving is inhibited: ##STR00001##

An organic electroluminescent element including a substrate, a pair of electrodes including an anode and a cathode, disposed on the substrate, and at least one organic layer including a light emitting layer, disposed between the electrodes, in which at least one kind of compound represented by the following general formula is contained in any layer of the at least one organic layer, is an organic electroluminescent element, in which the generation of dark spots during driving is inhibited: ##STR00001##

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent device having a low driving voltage and/or a high luminous efficiency and/or a long lifespan can be provided, by comprising an organic electroluminescent compound according to the present disclosure.

Compounds of the formula I ##STR00001## in which R.sup.1 denotes A, Ar, Cyc, Het, COA or CN, R.sup.2 denotes SO.sub.2A, SOA, SA, SO.sub.2NHA, SO.sub.2NA.sub.2, S(═NH,═O)A, S(═NH).sub.2A, NO.sub.2, Hal, CN, A, Het.sup.1, COOH or COOA, R.sup.3 denotes H or Hal, R.sup.4 denotes H or Hal, n denotes 1, 2 or 3, A denotes unbranched or branched alkyl having 1-6 C-atoms, Cyc denotes cyclic alkyl with 3 to 7 C-atoms, Ar denotes phenyl, Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, Het.sup.1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, and Hal denotes F, Cl, Br, or I, are inhibitors of HIF-2α, and can be employed for the treatment of diseases such as cancer.

Compounds of the formula I ##STR00001## in which R.sup.1 denotes A, Ar, Cyc, Het, COA or CN, R.sup.2 denotes SO.sub.2A, SOA, SA, SO.sub.2NHA, SO.sub.2NA.sub.2, S(═NH,═O)A, S(═NH).sub.2A, NO.sub.2, Hal, CN, A, Het.sup.1, COOH or COOA, R.sup.3 denotes H or Hal, R.sup.4 denotes H or Hal, n denotes 1, 2 or 3, A denotes unbranched or branched alkyl having 1-6 C-atoms, Cyc denotes cyclic alkyl with 3 to 7 C-atoms, Ar denotes phenyl, Het denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, Het.sup.1 denotes a mono- or bicyclic aromatic, unsaturated or saturated heterocycle having 1 to 4 N, O, and/or S atoms, and Hal denotes F, Cl, Br, or I, are inhibitors of HIF-2α, and can be employed for the treatment of diseases such as cancer.

The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.

Bis-amide inhibitors of SARS-CoV-2 (COVID); pharmaceutical compositions comprising same; and methods of treating a severe acute respiratory syndrome.

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

##STR00001##